CDNA · CareDx, Inc. · Stock research

Current Thesis

The leg on offer is a reimbursement-driven volume-and-margin compounding story that has just been validated by numbers. The 2026-07-16 finalized MolDX Local Coverage Determination removed the surveillance-coverage overhang that had capped this equity since 2023; the 2026-07-30 Q2 report converted policy into P&L — revenue $132M (+52% YoY), testing services $100M (+61% YoY), adjusted EBITDA $25M against $5M a year earlier. Management then raised FY2026 revenue guidance to $490–500M from $447–465M and adjusted EBITDA to $66–78M from $43–57M. What an investor is buying now is the estimate-revision stream, not the policy event itself: the LCD only takes effect 2026-08-30, and management sized its 2026 contribution at roughly $7.5M of six-month partial benefit, which places the reimbursement economics mostly in 2027. The complication is entry geometry. The 2026-08-07 close of $46.69 sits 2.4% under the $47.85 52-week high after a 114% three-month advance, with RSI(14) at 70.1 and HC Wainwright's 2026-07-31 Neutral target of $46 sitting essentially at the market.

Bullish and bearish views on CareDx, Inc.

The model's bull view on CareDx, Inc. (CDNA), in brief: Q2 2026 (reported 2026-07-30) beat on both lines: adjusted EPS $0.37 vs $0.23 consensus; revenue $131.948M vs $114.044M consensus. The bear view: Price is at or through most published targets. Both cases follow in full.

Bull Case

• Q2 2026 (reported 2026-07-30) beat on both lines: adjusted EPS $0.37 vs $0.23 consensus; revenue $131.948M vs $114.044M consensus. Testing services revenue $100M, +61% YoY.
• Guidance raised twice in fifteen days. FY2026 revenue went $420–444M → $447–465M (2026-07-16, with the LCD) → $490–500M (2026-07-30), against a $455.9M consensus. The $495M midpoint implies roughly 30% YoY growth. FY adjusted EBITDA guide moved to $66–78M from $43–57M.
• Margin inflection is visible, not promised. Non-GAAP gross margin 74% in Q2; adjusted EBITDA 19% of revenue in the quarter versus a ~15% full-year guide midpoint, implying management is not extrapolating the Q2 rate.
• Volume framework disclosed. ~58,000 tests in Q2 (+17% YoY), FY2026 guided to 258,000–266,000 — a checkable number every quarter rather than a narrative.
• Balance sheet repaired. Cash and equivalents $373.6M at 2026-06-30, after the Lab Products sale to Eurobio Scientific ($171.2M, closed 2026-06-30).
• Second surveillance franchise added. Naveris closed 2026-07-01 for $160M upfront plus up to $100M in revenue milestones; its NavDx TTMV-DNA assay for HPV-driven cancer MRD has held Medicare coverage since 2023, extending the recurring-surveillance model beyond transplant.
• Sell-side is still catching up. BTIG went $28 → $45 (2026-07-16) → $60 (2026-08-06); Craig-Hallum upgraded to Buy on 2026-08-03 arguing the raised guidance is conservative.

Bear Case

• Price is at or through most published targets. HC Wainwright reiterated Neutral with a $46 target on 2026-07-31, below the 2026-08-07 close of $46.69. Aggregated consensus figures compiled by stockanalysis.com in early August still showed a mean near $26 with a high of $40, which excludes BTIG's $60 — the aggregate lags, and the gap between it and spot is large either way.
• No base under the tape. +114% over three months, RSI(14) 70.1, 2.4% from the high. Every buyer since 2026-07-16 is positioned above two unfilled gaps.
• The GAAP quarter is flattered. Q2 GAAP net income of $111M includes a $113M gain on the Lab Products divestiture, excluded from non-GAAP. Underlying earnings power is $25M of quarterly adjusted EBITDA on $132M of revenue.
• Growth composition is price/mix-led. Testing-services revenue grew 61% YoY against 17% volume growth. Inferred, not disclosed: the majority of the delta is reimbursement rate and mix, which is a policy variable rather than a demand variable, and it does not compound the way volume does.
• The 2023 precedent is the risk case. The prior MolDX surveillance restriction erased roughly 85% of market capitalisation, taking the shares from ~$70 toward a $10.96 low. The same contractor that granted coverage on 2026-07-16 can clarify frequency limits after 2026-08-30.
• Naveris is unquantified inside the guide. The Q2 release did not break out NavDx revenue, and up to $100M of contingent milestone consideration sits behind the $160M already paid.

Setup & Price Structure

• Reference basis: 2026-08-07 close $46.69; 52-week high $47.85 (-2.4%); RSI(14) 70.1; three-month return +114%.
• Two stacked gaps define the structure. The 2026-07-16 LCD session ran from roughly $29.56 intraday to a $39.87 close, leaving an unfilled band around $30–$37. The 2026-07-30 print produced the second leg into the mid-$40s. The $39.87 gap-up close and the pre-print 52-week high of $40.47 now form the first real shelf.
• Life-cycle stage: ACCELERATING. The dates: guidance raised 2026-07-30, Craig-Hallum upgrade to Buy 2026-08-03, BTIG target to $60 on 2026-08-06 — three revision events in eight sessions, with published consensus aggregates still far below spot. That is a revision cycle in progress rather than a finished one. It flips to MATURING the moment the target-raise stream stops and the aggregate closes the gap to price without new fundamental news; it flips to SATURATED if the 2026-08-30 effective date and the Q3 print pass with the stock making no new high.
• Crowding and positioning observables, stated as observables: RSI(14) 70.1 within 2.4% of the 52-week high; retail-facing coverage clustering — the name appeared in Benzinga "stocks moving" screens on 2026-07-16, 2026-07-30 and 2026-07-31; three analyst actions inside eight sessions post-print; one already-elapsed binary (the Q2 print) resolved favourably, so the next hard number check is a full quarter away. The recent filings record reviewed for this note surfaced no Form 4 insider sales and no equity issuance into the advance — the absence is worth re-checking after each Form 4 window given the size of the move.
• The heavy binary in the calendar has already resolved. What remains inside 30 days is mechanical: coverage begins, and the market either sees follow-through in the revision stream or it does not.

Catalyst Calendar (next 30 days)

• 2026-08-30 — MolDX LCD effective date. Surveillance dd-cfDNA coverage for kidney, heart and lung recipients formally begins. Management sized 2026 impact at roughly $7.5M (six-month partial), so this date matters less for the print than for whether any contractor billing/coding article accompanies it with frequency limits.
• ~2026-09-30 (est.) — first full quarter carrying Naveris/NavDx. The September quarter is the first with the oncology asset for the whole period and without Lab Products, so the Q3 revenue line becomes the first clean read on the post-divestiture mix.
• ~2026-10-29 (est.) — Q3 2026 print. Beyond the 30-day window, flagged because it is the next event that can confirm or break the $490–500M FY guide and the 258,000–266,000 volume range.

What Would Change Our Mind

The structural claim is that surveillance reimbursement is now durable and compounds into 2027. Three things would falsify it. First, structure: the 2026-07-16 gap-up close of $39.87 and the pre-print 52-week high of $40.47 are the shelf the entire re-rate sits on — a weekly close below $40 gives back both and puts the unfilled $30–$37 band back in play, which is the market pricing the coverage decision as less valuable than it looked on 2026-07-30. Second, policy: any MolDX or CMS clarification after 2026-08-30 that limits testing frequency, or narrows the covered organ set, restores the exact overhang that was removed. Third, numbers: FY2026 revenue guidance trimmed below $490M at the Q3 print, or testing-services revenue growth decelerating toward the ~17% volume growth rate — which would show the 61% testing-services growth was a one-time rate reset rather than a durable trajectory. A fourth, softer condition: 2026-08-30 arrives, the analyst target raises stop, and the stock fails to take out $47.85 — that is the stage flipping to SATURATED with no new bid behind it.

Correlation Notes

• MolDX/CMS policy beta. The name trades with the LDT reimbursement complex — Natera, Exact Sciences, Guardant Health, Veracyte. A single MAC policy action can move the group; CareDx's 2023 drawdown is the extreme historical case of that correlation.
• Direct competitive read. Natera's Prospera is the closest dd-cfDNA transplant comparator; any Natera disclosure on transplant volumes or pricing is a direct read-through to CareDx's 58,000-test quarterly base.
• Mix discontinuity breaks the comps. With Lab Products divested 2026-06-30 and Naveris added 2026-07-01, YoY revenue-line comparisons through the next several quarters are not like-for-like; the volume series (tests) is the cleaner cross-period metric.
• Small/mid-cap diagnostics factor. Newly-EBITDA-positive diagnostics names carry high beta to XBI/IBB risk appetite and to rate expectations; a group-wide de-rating would pressure the multiple independent of anything CareDx reports.